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Hematopoietic stem cell transplantation (HCT) is a curative intervention in non-malignant
disorders (NMD) that benefit from donor-derived hematopoiesis, immunity, and
establishment of vital cells or enzyme systems. Stability or reversal of disease symptoms
depends on adequacy and long-term stability of donor cell engraftment in the
compartment of interest. Unlike hematologic malignancies where complete replacement
with donor derived hematopoiesis is desirable for a cure, NMD manifestations can
often be controlled in the presence of mixed chimerism. This allows for exploration
of reduced intensity conditioning regimens that can limit organ toxicity, late effects,
and increase tolerability especially in young recipients or those with a large burden of
disease related morbidity. However, the levels of donor chimerism conducive to disease
control vary between NMD, need to focus on the hematopoietic lineage necessary to
correct individual disorders, and need to be assessed for stability over time, i.e., a
whole lifespan. An enhanced ability to reject grafts due to recipient immune competence,
alloimmunization, and autoimmunity add to the complexity of this balance making NMD
a highly diverse group of unrelated disorders. The addition of donor factors such as stem
cell source and Human-Leukocyte-Antigen match extend the complexity such that ‘one
size does not fit all’. In this perspective, we will discuss current knowledge of the role of
chimerism and goals, approach to HCT, and emerging methods of boosting engraftment
and graft function, and monitoring recommendations. We draw attention to knowledge
gaps and areas of necessity for further research and research support.
Keywords: chimerism, chimerism after allo-HSCT, non-malignant diseases, hematopoeietic stem cell
transplantation, bone marrow failure disorders, hemoglobinopathies, immunodeficiencies, metabolic disorder
INTRODUCTION
Hematopoietic stem cell transplantation (HCT) is a curative option in a variety of inherited and
acquired non-malignant disorders (NMD) that present at varying age groups, progress at variable
rates, and have a wide range of clinical manifestations. These can vary from chronic supportive
care needs and poor quality of life to rapid progression and early mortality. The overall aim of
HCT is to correct the pathologic basis of hematologic, immunologic, or enzymatic dysfunction
that is the etiology of the underlying disease. HCT results in immunohematologic replacement and
thus corrects pathophysiology in NMD such as immune deficiencies and dysregulation, metabolic
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disorders, hemoglobinopathies, and bone marrow failure
disorders. As identification of genetic abnormalities become
more sophisticated, indications for curative transplant are
expected to rise. As the number of disorders benefiting from
transplant increase, expansion of donor sources that will
best serve to mitigate disease manifestations is advantageous.
Though HCT is curative, the risk-benefit ratio between
disease manifestations and HCT outcomes should be carefully
considered. The safety and efficacy of the procedure factors
into the decision on how to, when to, and what to monitor
post-transplant. Ensuring adequate and stable donor engraftment
to effectively suppress disease manifestations or afford a cure in
timely manner has a major role in determining outcomes and
success when HCT is contemplated for NMD. Successful HCT
does not guarantee reversal of non-hematopoietic abnormalities
and outcomes are variable depending on disorder, graft source,
conditioning regimen, toxicity, and other factors. We will focus
on the chimerism aspect of success following HCT for NMD.
CHIMERISM
Full donor chimerism is often unnecessary in NMD provided
lineage specific engraftment is adequate to cure or suppress
disease manifestations. However, a few scenarios give
pause to this conclusion and disease specific assessment of
chimerism requirement is necessary. Examples include metabolic
neurodegenerative disorders where prompt and high percentage
donor engraftment is required to stem neurodegeneration as
early as possible and ensure an early rise in protective enzyme
levels (1). Patients with inherited marrow failure disorders
have a predisposition to myeloid malignancies. The stress of
hematopoiesis has been implicated in malignant transformation,
a stress relieved by successful HCT. It is not known whether this
is adequate protection against transformation to leukemia in the
setting of mixed chimerism post-HCT, making a case for regular
long-term follow up in all HCT recipients.
Frequency
Chimerism should be monitored at regular intervals after
HCT. Though the duration of monitoring is variable, it is
recommended that chimerism be monitored for at least 5 years
post-HCT. The frequency of monitoring is higher in the first
year post-HCT starting from the time of established engraftment,
∼30 days post-HCT. In the presence of complete chimerism,
monitoring every 3 months in the first year, 6 months in
the second year and yearly for at least 5 years is a general
guideline. In the event of unstable or mixed chimerism, intervals
between testing should be shorter to determine additional
interventions such as immunosuppression, stem cell boosts, or
second transplant. Chimerism analysis should be paired with
disease specific evaluations such as hemoglobin analysis in
hemoglobinopathies, blood counts in marrow failure disorders,
immune recovery in immunodeficiency disorders, and enzyme
levels in metabolic disorders. In the event of poor marrow
function it is important to determine whether the problem is
due to lack of engraftment or poor graft function. Since etiology
is often immune mediated in the former and a product of the
marrow environment or donor source in the latter, the approach
to investigation and mitigation vary. In general, a rapid drop of
donor chimerism early post-HCT is difficult to halt. A gradual
loss of engraftment over timemay bemore conducive to planning
interventions that can help slow or prevent graft loss.
Methods
Chimerism is detected by short tandem repeat (STR) polymerase
chain reaction (PCR) analysis that quantifies donor and recipient
DNA using individual specific repeats. It is read as a percentage of
donor and recipient DNA in the sample, which can be peripheral
blood or marrow. This procedure is the most sensitive and
accurate method of testing. Pre-transplant samples from both
donor and recipient are necessary for reporting post-HCT results.
Alternate methods include florescent in-situ hybridization
(FISH), chromosome analysis for sex chromosomes in the
presence of sex discrepancy between donor and recipient,
markers of donor hematopoiesis such as change in blood type,
and a rise in previously absent enzyme levels in hereditary
metabolic disorders. Disease specific testing such as neutrophil
oxidative burst in chronic granulomatous disease or CD40 ligand
expression in hyper-IgM syndrome can also assist in determining
transplant efficacy. The latter tests are cheaper and can be used for
screening but are not an accurate prediction of chimerism status.
Lineage Specific Assessment
Most non-malignant disorders require lineage specific chimerism
assessment which provides valuable detail despite the cost.
Tracking chimerism in this manner allows for prediction of the
role of chimerism on disease status and correction of deficit.
Lineage specific evaluation is based on positive selection from
peripheral blood cells and includes antibody column mediated
cell separation into myeloid (CD15, CD33), T lymphoid (CD3),
and B (CD19) lineage specificity followed by STR analysis.
Additional less frequently used assessments of lineage specific
chimerism include NK cells (CD16/CD56) or erythroid lineage
cells (CD71) for appropriate disorders. Lower levels of mixed
chimerism in non-essential lineages with stable full or adequate
donor chimerism in the lineages of interest is capable of
providing a cure. Serial tracking is necessary until stability
is ensured.
In disorders where single lineage abnormalities cause disease,
relevant lineage specific engraftment may be curative. For
example, complete lymphoid engraftment with low myeloid
chimerism (<50% donor) in Wiskott Aldrich syndrome can
reverse the immune deficiency but not the thrombocytopenia.
Serial determination of lineage specific chimerism can help
predict impending rejection specific to each disease and facilitate
earlier intervention (2).
Lineage specific chimerism requires an adequate number of
lineage specific cells to determine chimerism levels. In the case
of T-cell depleted transplants, reconstitution of the lymphoid
compartment may be delayed. This may delay meaningful T-
cell engraftment analyses. Similarly in the event of bone marrow
suppression from factors such as infection, myeloid chimerism
analyses may need to be performed after myeloid recovery.
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DISEASE SPECIFIC CHIMERISM
Children transplanted for NMD have a wide range of mixed
chimerism where donor cell engraftment ranges from 33 to 78%
(3–5). This variability is attributed to disease characteristics,
immune competence, conditioning regimen, donor source, and
transplant related complications. A retrospective review of
an Italian cohort of 101 patients who underwent transplant
for NMD found that chimerism remained a dynamic process
where 55.4% of patients with early mixed chimerism post-HCT
improved to only 12.8% with mixed chimerism at last follow-
up (6). However, late graft failure though rare was still prevalent,
making the case for continued follow-up. Early complete donor
chimerism can correct disease manifestations sooner. However,
early alloreactivity from donor lymphocyte engraftment can
be associated with a higher incidence of both acute and
chronic graft-versus-host (GVHD) disease. Mixed chimerism
and gradual donor lymphoid engraftment invites tolerance and
has a lower incidence of GVHD (6). A retrospective review
of 56 patients transplanted for NMD showed that chimerism
assessment on day+14 was significant in predicting 5-year event-
free survival (EFS). It was higher in patients with complete or
predominant donor chimerism compared to those with low-level
mixed chimerism (86.1 vs. 71.4%, p < 0.001) (7). Our experience
is similar in that a rapid decrease in donor engraftment early
post-transplant suggests robust immunologic rejection and is
harder to control without consideration of a second transplant.
The extensive variability in NMD makes it worthwhile to
summarize chimerism studies by disease groups.
IMMUNE DEFICIENCIES
Immune deficiencies that benefit from HCT are widely variable
in the range of immune defects exhibited, some with additional
hematologic manifestations. The most common disorders
include severe combined immunodeficiency (SCID), Wiskott-
Aldrich syndrome (WAS), and chronic granulomatous disease
(CGD). The majority present during early childhood and SCID
patients may be identified at birth with newborn screening.
Immune dysregulation disorders that respond to treatment with
HCT include hereditary hemophagocytic lymphohistiocytosis
(HLH), immunodysregulation polyendocrinopathy
enteropathy X-linked syndrome (IPEX), and autoimmune
lymphoproliferative syndrome (ALPS). Non-SCID immune
disorders are diagnosed at various ages most commonly due
to infectious complications or hematopoietic/autoimmune
manifestations. HCT provides the opportunity to establish a
normal immune system but is a serious undertaking due to the
risks associated with treating very young, or patients already
exposed to serious infections. HCT is considered successful
if patients demonstrate successful immune reconstitution in
all lymphoid compartments, normal immunoglobulin levels,
vaccine response, and T-cell repertoire. Achieving this in
the presence of a dysregulated host immune system can be
challenging given the propensity for selective engraftment and
partial correction.
Patients with SCID have excellent survival rates post-HCT.
Due to T-cell deficiency and the associated inability to reject
grafts, for many years, the standard of care for SCID patients was
to infuse donor stem cells without conditioning. This led to donor
T-cell engraftment while other lineages remained of recipient
origin resulting in lifelong dependency on immunoglobulin
(IVIG) infusions due to a lack of functional B-cells in some SCID
subtypes such as RAG1/2 deficiency.
Recently, retrospective reviews have shown that T-cell
reconstitution was poorer with RAG and DCLRE1C mutations
than other phenotypes. B-cell engraftment was poorer in
IL2RG/JAK3, RAG and DCLRE1C mutation phenotypes
especially with mismatched grafts (8, 9). With T-cell replete
grafts, if at day +100, recipients had <300 CD3 cells/µL, <50
CD8 cells/µL, <10% CD45RA cells or a T cell repertoire of <13
of 24 families, a second HCT was likely needed (10). Global
immune reconstitution has been successfully achieved in typical
or leaky SCIDs transplanted after reduced intensity conditioning
regimens. In contrast to T-cell engraftment, myeloid and B-cell
reconstitution is improved by conditioning strength with
myeloablative HCT affording better engraftment than reduced
intensity HCT (11). Factors to be considered for toxicity of
intensive regimens however include age of the patients, potential
for late effects, pre-existing infections, and toxicity due to
DNA repair defects (DCLRE1C). Another strategy to improve
outcomes may be to avoid conditioning before an initial stem
cell infusion if toxicity is imminent. This will need to be followed
by a subsequent HCT with conditioning complete immune
reconstitution when the recipient can tolerate it better.
All other immune deficiency disorders other than SCID
require conditioning for engraftment. While myeloablative
regimens have been associated with significant morbidity,
reduced intensity regimens have better survival but higher
rejection rates (12). Donor chimerism of >30% if stable, can
protect against disease reactivation in HLH (13). Stable myeloid
chimerism levels of >50% are desirable in conditions such
as CGD for functional correction, and platelet count recovery
in WAS. If familial donors are considered, the presence of
heterozygosity for disease in the donor will need to be considered
as it may interfere with full correction of the disease (e.g., HLH,
X-linked CGD). Here, carrier donors are best avoided. Some
immune dysregulation disorders such as STAT1 or CTLA-4
deficiency may require full donor chimerism for correction.
Reducing the intensity or toxicity for safety may have secondary
or late rejection rates of 10–15%, (14), autoimmunity with mixed
chimerism (15) or delayed myeloid engraftment (16) and need
to be tracked. Despite this, success rates continue to improve for
these disorders.
METABOLIC AND STORAGE DISORDERS
Metabolic and storage diseases are a heterogeneous group of
disorders leading to accumulation of enzymatic by-products
in multiple organs with associated toxicities, predominantly
neurologic. HCT from unaffected donors can supplement
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enzyme following hematopoietic engraftment and migration
to affected organs. Timely HCT is important to offset
irreversible changes making early engraftment a key determinant
of success.
Hurler Syndrome, a lysosomal storage disorder caused by
deficiency of the enzyme alpha-L-iduronidase (IDUA) is themost
commonly transplanted inheritedmetabolic disorder. Transplant
is considered successful when patients attain normal leukocyte
IDUA levels best achieved with full donor chimerism. In a study
of more than 200 patients transplanted for Hurler’s followed for
neurodevelopmental outcomes and growth, factors supporting
successful enzyme reconstitution included early transplantation,
non-carrier donors, cord blood grafts due to higher inherent
enzyme levels, and preparative regimens designed to achieve
complete chimerism (1, 17). Speed of HCT for engraftment
has no better illustration than early infantile Krabbe disease
where donor engraftment following HCT <30 days of age had
improved outcomes in domains of mobility, communication and
feeding (18).
Leukodystrophies such as adrenoleukodystrophy (ALD), an
X-linked disorder resulting in the inability to transport fatty acids
into the peroxisome for degradation leads to accumulation in
tissues specifically the central nervous system. HCT has been
shown to halt neurological disease progression in a significant
majority attributed to monocyte engraftment in the brain. It is
important to proceed to transplant at diagnosis and with a low
Loes radiologic score. Neurologic stability after engraftment takes
time and occurs over the span of the first year so delays could
accelerate deterioration. ALD patients with 70–100% donor
chimerism in the myeloid compartment on day +60 and those
with faster recovery of neutrophil counts had better resolution of
gadolinium uptake on brain MRI scans post-HCT, a measure of
blood brain barrier recovery (19).
Osteopetrosis, characterized by dysfunctional osteoclasts, also
responds to HCT. Stabilization of vision and hearing, nasal
obstruction and motor deterioration requires transplant in
infancy and prompt engraftment is able to rescue 40–70%
of patients. Graft failure despite intensive conditioning is the
major cause of failure and death after HCT in osteopetrosis.
However, donor chimerism in myeloid cells as low has
5–10% prevents death and provides sustained hematopoietic
recovery in contrast to many other hereditary metabolic
disorders (20).
HEMOGLOBINOPATHIES
Hereditary hemoglobinopathies with severe manifestations can
be cured by HCT. The common disorders eligible for HCT are
sickle cell disease (SCD) and transfusion dependent thalassemia.
Variables influencing donor engraftment in hemoglobinopathy
patients include age, HLA alloimmunization due to transfusion
history, immune competence, and paucity of matched sibling
donors. SCD manifestations are reversed in the presence of
successful donor-derived erythropoiesis and normal erythroid
precursors may have a survival advantage resulting in abatement
of SCD symptoms even in the presence of low lymphoid
engraftment. Myeloid lineage chimerism is a good surrogate
for erythropoiesis in the absence of red cell chimerism (CD71)
evaluation. Lymphoid engraftment can remain low or increase
over time but there are no threshold levels necessary to maintain
myeloid engraftment (21, 22).
Stable donor chimerism >20–25% paired with a hemoglobin
S level <50% is associated with resolution of disease symptoms
such as vaso-occlusive episodes and strokes (23, 24). However,
hemolytic anemia was detected in SCD patients who had
<50% donor cells after myeloablative conditioning and higher
engraftment levels (>30%) were better if donors had sickle
trait (25). The acceptability of stable mixed chimerism and
the presence of mixed chimerism even with myeloablative
conditioning (up to 44%) allows the exploration of less toxic
regimens for HCT in SCD. Younger patients and donors, those
with mismatched donors, low cell dose, and weaker stem cell
sources such as cord blood have a higher risk of graft rejection
in SCD and should be taken into consideration when fashioning
regimens targeting intensity (26).
Thalassemia is cured when a patient no longer requires blood
transfusions, regains growth, and restores iron related changes.
A cohort of 106 patients with beta-thalassemia major when
studied retrospectively revealed that half had sustained mixed
donor chimerism with cure. Mixed chimerism was associated
with a good transplant outcome and decreased risk of acute
or chronic GVHD, a finding that was not noted in SCD. High
erythroid lineage engraftment with low level donor chimerism in
other lineages is compatible with cure in thalassemia (27). Mixed
chimerism though acceptable, needs monitoring for stability over
time in patients with hemoglobinopathy irrespective of intensity
of conditioning regimens.
TABLE 1 | Classification of non-maligant disorders with associated lineage
specific engraftment, and recommended donor chimerism levels for adequate
disease mitigation.
Non-malignant disorder Lineage specificity Minimum goal for
donor Chimerism
Immunodeficiencies
HLH NK cell/Lymphoid >30% (13)
IPEX, ALPS Lymphoid >50% (32)
Severe Combined
Immunodeficiency




Wiskott-Aldrich Syndrome Lymphoid/Myeloid >50% (16)
Hemoglobinopathies
Sickle Cell Disease Erythroid/myeloid 20–25% (23)
Thalassemias Erythroid/myeloid 20–25% (27)
Metabolic disorders
ALD, Hurlers, Krabbe’s Myeloid 70–100% (1)
Osteopetrosis Myeloid >10% (20)
Bone marrow failure syndromes
SCN, SDS, DBA, FA Myeloid 100% (30)
Lymphoid >50% (31)
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BONE MARROW FAILURE SYNDROMES
Bone marrow failure syndromes (BMFS) such as aplastic
anemia, severe congenital neutropenia, dyskeratosis congenita,
Shwachman-Diamond, Diamond-Blackfan or Fanconi anemias
(FA), and congenital amegakaryocytic thrombocytopenia include
genetic and acquired pathologies resulting in inadequate
hematopoiesis. HCT is curative. Since many are pre-leukemic
conditions, full donor chimerism in the myeloid compartment
is desirable and mixed chimerism in lymphoid lineages is
acceptable. Patients with Fanconi and DNA repair defects are
unable to tolerate regimen intensity or alkylating agents. The
resulting need for balance between toxicity of intensification
and engraftment is delicate. Graft rejection rates can be as high
as 20–25% even with myeloablation. Both myeloablative and
immunosuppressive regimens have been successful in curing
BMFS following successful myeloid engraftment. In FA, with
mixed chimerism in the lymphoid lineage, patients can be
left with some lymphocytes exhibiting the increased sensitivity
to DNA damage and others exhibiting a normal response
(28–31). Long-term follow-up post-HCT in all BMFS should
include both chimerism evaluation and monitoring for clonal
hematopoiesis, a risk that should technically be mitigated with
myeloid engraftment.
DISCUSSION
Donor chimerism requirements to achieve disease control are
widely variable in NMD and can range from as low as 10%
to >90% (Table 1). Variables influencing chimerism include
age, inflammatory status, immune competence, and transfusion
history. Transplant and donor characteristics include donor
age, HLA match, stem cell source, cell dose, and intensity of
conditioning regimens. In general, reduced intensity regimens
are more appropriate for disorders that are conducive to mixed
chimerism. As transplant approaches change to accommodate
more donors, increase safety and tolerability, and reduce toxicity,
chimerism should be tracked and described long-term.
Our understanding of chimerism and adequate interventions
for the same continue to evolve. Stable donor chimerism off
immunosuppression for over 2 years is unlikely to dwindle.
However, continued monitoring is still recommended for
occasional late graft rejections as described in thalassemia. These
patients are usually identified by gradually dwindling donor
chimerism levels in the lineage of interest. The old dogma
that T-cell engraftment was necessary to maintain myeloid
chimerism has not held true in NMD following the expanded
ability to monitor chimerism in a lineage specific manner.
While stable mixed chimerism is fully acceptable, dropping
chimerism has prompted immune suppression withdrawal in
myeloablated or immunoablated recipients whereas continuing
immune suppression has been advantageous in low intensity
regimens. Donor lymphocyte infusions are generally not of
benefit, can induce unwanted GVHD, and should be avoided
in NMD. An early rapid drop in chimerism usually requires
a second stem cell infusion after reconditioning whereas a
gradual decline can be salvageable with immune suppression
adjustments. Reduced intensity conditioning does not preclude a
second early transplant whereas a time lag is better for toxicity
reasons after a myeloablative transplant. The ability to infuse
products such as high dose CD34 selected stem cells is valuable
in NMD to avert GVHD risks.
CONCLUSIONS
The tracking of lineage specific donor chimerism for
stability with time should be routinely incorporated into
evaluations post-HCT for NMD. The definition of adequate
chimerism for successful HCT varies by disorder and as
our understanding of the same matures, our remedial
interventions will evolve. The definition and durability of
adequate chimerism has direct application to gene-modified
therapy that is now under evaluation for many genetic
disorders. In both the allogeneic and in the gene-modified
autologous HCT setting, chimerism requirements will drive
conditioning needs and transplant methods to achieve
a cure.
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